Results 271 to 280 of about 54,330 (287)

Acalabrutinib in mantle cell lymphoma

The Lancet, 2018
Prashant, Kapoor, Stephen M, Ansell
openaire   +2 more sources

Limited-stage mantle-cell lymphoma

Annals of Oncology, 2003
Randy D Gascoyne, Joseph M Connors
exaly  

Management of mantle cell lymphoma

Annals of Hematology, 1999
P, Meusers, J, Hense
openaire   +2 more sources

Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study

Annals of Oncology, 2002
Yukio Kobayashi, Kensei Tobinai
exaly  

Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma

New England Journal of Medicine, 2018
Constantine S Tam, Mary Ann Anderson, Rishu Agarwal   +2 more
exaly  

Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma

New England Journal of Medicine, 2015
Peter Martin, Sonali M Smith, Jakub Svoboda   +2 more
exaly  

Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study

Annals of Oncology, 2009
Benjamin Djulbegovic, André Goy
exaly  

Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes

Annals of Oncology, 2015
Dai Chihara, Nathan Fowler, John F Seymour   +2 more
exaly  

Is there an increased rate of additional malignancies in patients with mantle cell lymphoma?

Annals of Oncology, 2002
Fernando Cabanillas, Jorge E Romaguera, L Jeffrey Medeiros   +2 more
exaly  

Central nervous system involvement in mantle cell lymphoma

Annals of Oncology, 2008
Francesc Bosch, Elias Campo
exaly